MA28116A1 - Preparation solide comprenant un sensibilisateur a l'insuline, un secretagogue d'insuline et un ester d'acide gras de polyoxyethylene sorbitan - Google Patents

Preparation solide comprenant un sensibilisateur a l'insuline, un secretagogue d'insuline et un ester d'acide gras de polyoxyethylene sorbitan

Info

Publication number
MA28116A1
MA28116A1 MA28976A MA28976A MA28116A1 MA 28116 A1 MA28116 A1 MA 28116A1 MA 28976 A MA28976 A MA 28976A MA 28976 A MA28976 A MA 28976A MA 28116 A1 MA28116 A1 MA 28116A1
Authority
MA
Morocco
Prior art keywords
insulin
secretagogue
fatty acid
acid ester
polyoxyethylene sorbitan
Prior art date
Application number
MA28976A
Other languages
English (en)
Inventor
Kazuhiro Doken
Tetsuya Kawano
Hiroyoshi Koyama
Naoru Hamaguchi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34543966&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28116(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA28116A1 publication Critical patent/MA28116A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA28976A 2003-10-31 2006-04-28 Preparation solide comprenant un sensibilisateur a l'insuline, un secretagogue d'insuline et un ester d'acide gras de polyoxyethylene sorbitan MA28116A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003371679 2003-10-31

Publications (1)

Publication Number Publication Date
MA28116A1 true MA28116A1 (fr) 2006-08-01

Family

ID=34543966

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28976A MA28116A1 (fr) 2003-10-31 2006-04-28 Preparation solide comprenant un sensibilisateur a l'insuline, un secretagogue d'insuline et un ester d'acide gras de polyoxyethylene sorbitan

Country Status (28)

Country Link
US (1) US7700128B2 (fr)
EP (1) EP1677792B1 (fr)
KR (2) KR20100012105A (fr)
CN (1) CN1874774B (fr)
AR (1) AR046210A1 (fr)
AU (1) AU2004285354B2 (fr)
BR (1) BRPI0414979A (fr)
CA (1) CA2540225C (fr)
CY (1) CY1117176T1 (fr)
DK (1) DK1677792T3 (fr)
ES (1) ES2556244T3 (fr)
GE (1) GEP20084570B (fr)
HR (1) HRP20151447T1 (fr)
HU (1) HUE028576T2 (fr)
IL (1) IL174201A (fr)
JO (1) JO3106B1 (fr)
MA (1) MA28116A1 (fr)
MX (1) MXPA06004639A (fr)
NO (1) NO340294B1 (fr)
NZ (1) NZ546337A (fr)
PE (1) PE20050923A1 (fr)
PL (1) PL1677792T3 (fr)
PT (1) PT1677792E (fr)
RU (1) RU2359661C2 (fr)
SI (1) SI1677792T1 (fr)
TW (1) TWI339586B (fr)
WO (1) WO2005041962A1 (fr)
ZA (1) ZA200602056B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220881A1 (en) * 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
TWI384985B (zh) * 2005-12-22 2013-02-11 Takeda Pharmaceutical 固體製劑
CN101478966B (zh) 2006-06-27 2013-08-21 第一三共株式会社 压缩制剂
BRPI0807453B8 (pt) * 2007-02-01 2021-05-25 Takeda Pharmaceuticals Co preparação sólida
IS8660A (is) * 2007-07-02 2009-01-03 Actavis Group Ptc Ehf. Gliklasíð lyfjasamsetning
WO2009120844A2 (fr) * 2008-03-26 2009-10-01 Teva Pharmaceutical Industries Ltd. Compositions pharmaceutiques comprenant un sensibilisateur à l’insuline et un secrétagogue d’insuline
CA2782776A1 (fr) 2008-12-04 2010-06-10 Ikfe Gmbh Marqueurs biologiques de l'atherosclerose
US20110118134A1 (en) 2008-12-11 2011-05-19 Ikfe Gmbh Biomarkers for insulin sensitizer drug response
WO2010076655A1 (fr) 2008-12-30 2010-07-08 Ikfe Gmbh Biomarqueurs de l'activité des tissus adipeux
EP2382475A2 (fr) 2009-01-07 2011-11-02 IKFE GmbH Marqueurs biologiques pour la régulation de l'appétit
US8623345B2 (en) * 2009-03-20 2014-01-07 Smartcells Terminally-functionalized conjugates and uses thereof
EP2618827B1 (fr) * 2010-09-21 2021-06-02 Intekrin Therapeutics, Inc. Compositions pharmaceutiques solides antidiabétiques
EP2438911A1 (fr) * 2010-10-08 2012-04-11 LEK Pharmaceuticals d.d. Compositions pharmaceutiques comprenant du secrétagogue d'insuline de classe suphonylurée et huile de ricin à base de glycol de polyéthylène
WO2013034174A1 (fr) * 2011-09-06 2013-03-14 ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. Préparations solides de pioglitazone et de glimépiride
CN104288161A (zh) * 2014-09-19 2015-01-21 四川海思科制药有限公司 一种含吡格列酮格列美脲的药物组合物
CA2979033A1 (fr) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methodes de traitement de la steatose hepatique non alcoolique et/ou de la lipodystrophie
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5865213A (ja) * 1981-10-13 1983-04-18 Tokai Kapuseru Kk ｄｌ−２−（４，８，１２−トリメチルトリデシル）−２，５，７，８−テトラメチル−６−クロマニルニコチネ−ト軟カプセル剤
US4620974A (en) * 1983-07-07 1986-11-04 American Home Products Corporation Pharmaceutical composition containing a liquid lubricant
JP2764274B2 (ja) * 1988-03-28 1998-06-11 株式会社ミドリ十字 医薬組成物
PT726761E (pt) 1993-11-03 2001-07-31 Isomed Inc Composicoes farmaceuticas que microparticulas na forma de micelios
HU212428B (en) * 1994-05-13 1996-06-28 Egyt Gyogyszervegyeszeti Gyar Process to prepare pharmaceutical compositions containing gemfibrozyl
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
FR2758461A1 (fr) * 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6291495B1 (en) 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
AP1600A (en) * 1997-06-18 2006-04-28 Smithkline Beecham Plc Combination of a thiazolidinedione and a sulphonylurea for treating diabetes
GB9715298D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715295D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
EA002806B1 (ru) * 1997-09-11 2002-10-31 Нюкомед Данмарк А/С Многоединичные композиции с модифицированным высвобождением нестероидных противовоспалительных лекарственных веществ (nsaid)
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
BR9915285A (pt) 1998-11-12 2001-08-07 Smithkline Beecham Plc Composição farmacêutica para liberação modificada de um sensitivador de insulina e um outro agente antidiabético
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
CA2386517A1 (fr) 1999-10-07 2001-04-12 Takeda Chemical Industries, Ltd. Derives d'amines
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
ATE479429T1 (de) 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
AU2001256733A1 (en) 2000-05-16 2001-11-26 Takeda Chemical Industries Ltd. Melanin-concentrating hormone antagonist
EP1349531A1 (fr) 2001-01-12 2003-10-08 Sun Pharmaceuticals Industries Ltd. Systeme de liberation espacee de medicaments
US20050245571A1 (en) 2001-10-19 2005-11-03 Hidenori Abe Amine derivative
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
EP1552832A1 (fr) 2002-07-11 2005-07-13 Takeda Pharmaceutical Company Limited Procede de production d'une preparation recouverte
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040147564A1 (en) 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
NZ541749A (en) 2003-01-29 2009-06-26 Takeda Pharmaceutical Process for producing coated preparation comprising pioglitazone hydrochloride and a coating material
FR2853831A1 (fr) * 2003-03-05 2004-10-22 Usv Ltd Forme posologique solide a usage oral de metformine et de glyburide et son procede de preparation

Also Published As

Publication number Publication date
NO340294B1 (no) 2017-03-27
HUE028576T2 (en) 2016-12-28
PE20050923A1 (es) 2005-12-26
ES2556244T3 (es) 2016-01-14
JO3106B1 (ar) 2017-09-20
AU2004285354A1 (en) 2005-05-12
IL174201A0 (en) 2006-08-01
NZ546337A (en) 2009-03-31
ZA200602056B (en) 2007-05-30
KR20060061383A (ko) 2006-06-07
IL174201A (en) 2011-04-28
PL1677792T3 (pl) 2016-05-31
AR046210A1 (es) 2005-11-30
CA2540225C (fr) 2012-03-06
BRPI0414979A (pt) 2006-11-21
US20060223870A1 (en) 2006-10-05
NO20062515L (no) 2006-07-31
EP1677792A1 (fr) 2006-07-12
MXPA06004639A (es) 2006-06-27
WO2005041962A1 (fr) 2005-05-12
GEP20084570B (en) 2008-12-25
HRP20151447T1 (hr) 2016-02-12
RU2006118786A (ru) 2007-12-10
DK1677792T3 (en) 2015-12-14
TW200524641A (en) 2005-08-01
CY1117176T1 (el) 2017-04-05
AU2004285354B2 (en) 2009-09-17
KR100952090B1 (ko) 2010-04-13
PT1677792E (pt) 2016-02-09
KR20100012105A (ko) 2010-02-05
CN1874774B (zh) 2011-04-13
EP1677792B1 (fr) 2015-11-18
RU2359661C2 (ru) 2009-06-27
CN1874774A (zh) 2006-12-06
US7700128B2 (en) 2010-04-20
TWI339586B (en) 2011-04-01
SI1677792T1 (sl) 2016-02-29
CA2540225A1 (fr) 2005-05-12

Similar Documents

Publication Publication Date Title
MA28116A1 (fr) Preparation solide comprenant un sensibilisateur a l'insuline, un secretagogue d'insuline et un ester d'acide gras de polyoxyethylene sorbitan
MA27205A1 (fr) Preparations d'insuline acides presentant une stabilite amelioree
GB0428508D0 (en) Formulation containing a carboxylic acid or an ester thereof
MA26930A1 (fr) Esters oxygenes d'acides 4-iodophenylamino- benzhydroxamiques
ID29380A (id) Penhilangan konstituen gas asam dari gas
IL206889A0 (en) Site-specific incorporation of redox active amino acids into proteins
HK1073441A1 (en) Administration of a partial fatty acid oxidation inhibitor such as ranolazine for the treatment of diabetes
NO20021205D0 (no) Faste lipid formuleringer
AU2003294056A1 (en) Polyamino acids functionalized by at least one (oligo)amino acid group and therapeutic uses
FR2857263B1 (fr) Nouvelle composition pharmaceutique solide comprenant de l'amisulpride
ID27856A (id) Proses penyiapan derivat-derivat asam benzoik yang di ortho-alkilasi
DK1372728T3 (da) Sammensætning omfattende en olie-i-vand-emulsion indeholdende konjugeret linolensyre
DE69908621D1 (de) Aliphatische carbonsäurediester als nichtselektive herbizide
IL184848A0 (en) Polymorphis of a known thiophenecarboxylic acid dodecahydrocyclopenta (a) phenanthrenyl ester
DE60143052D1 (de) Lipid vom carbonsäuretyp
FI20020593A (fi) Menetelmä konjugoidun linolihapon valmistamiseksi
NO20050920L (no) Konjugert linolsyrepulver
HUP0105151A3 (en) Preparation of (s)-2-amino-6,6-dimethoxyhexanoic acid methyl ester via novel dioxolanes
AU2001271060A1 (en) Method of detecting lipid metabolic errors
EP1699448A4 (fr) Procede d'administration d'acide 3,3,14,14 tetramethyl hexadecane 1,16 dioique
AU2003273467A8 (en) Method of preparing an ester of an aromatic carboxylic acid bearing at least one perfluoroalkyl group
FR2869902B1 (fr) Composition, notamment cosmetique, comprenant un ester de ((dialkylamino)alcoxy) ethanol
AU2003224361A1 (en) Hepatoprotective activity of 2'-p-hydroxybenzoylmussaenosidic acid
RU95120050A (ru) Гербицидный состав
ID30120A (id) DERIVAT-DERIVAT ASAM ARENEKARBOKSILIK α-(1-PIPERAZINIL)-ASETAMIDO SEBAGAI AGEN-AGEN ANTIDIABETIS